Healthcare Resource Utilization and Costs in Celiac Disease: A US Claims Analysis.

"CONFLICTS OF INTEREST Guarantor of the article: Song Wang, PhD. Specific author contributions: K.C., A.T., B.H.J., S.W., M.G., and D.A.L. contributed to planning and conducting the study, interpreting the data, and drafting the manuscript. In addition, K.C. and S.G. contributed to collecting the data. All authors have read and approved the final version of this manuscript. Financial support: This study was funded by Takeda Pharmaceuticals International Co. Potential competing interests: A.T., S.W., M.G., and D.A.L. are employed by Takeda Pharmaceuticals International Co. K.C., B.H.J., and S.G. are employed by IBM Watson Health which received funding from Takeda Pharmaceuticals International Co. to conduct this study.Study HighlightsWHAT IS KNOWN✓ CeD is chronic and linked to a higher comorbidity burden.✓ Data on direct healthcare costs of CeD are limited and lack procedure-level detail.WHAT IS NEW HERE✓ Patients with CeD had higher 2-year healthcare costs than the controls matched on comorbidity burden and demographics.✓ Costs peaked in the first year after diagnosis and remained higher than the controls in the second year.✓ Outpatient services, including visits to specialists and use of diagnostic services, were the primary driver of high costs."

"Financial support: This study was funded by Takeda Pharmaceuticals International Co."